Molecular and clinical characterization of Galectin‐9 in glioma through 1,027 samples
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular and clinical characterization of Galectin‐9 in glioma through 1,027 samples
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-10-14
DOI
10.1002/jcp.29309
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC
- (2018) Jie Ji et al. Cell Death & Disease
- Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis
- (2018) Xiaoxiang Zhou et al. Frontiers in Physiology
- Primary brain tumours in adults
- (2018) Sarah Lapointe et al. LANCET
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Regulation of M1-type and M2-type macrophage polarization in RAW264.7 cells by Galectin-9
- (2017) Ran Lv et al. Molecular Medicine Reports
- The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
- (2017) Isabel Gonçalves Silva et al. EBioMedicine
- Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status
- (2017) Junlong Wu et al. Scientific Reports
- Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
- (2016) David Cella et al. LANCET ONCOLOGY
- Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Progress in glioma diagnosis, classification and treatment
- (2016) Patrick Y. Wen et al. Nature Reviews Neurology
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Prospects of immune checkpoint modulators in the treatment of glioblastoma
- (2015) Matthias Preusser et al. Nature Reviews Neurology
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
- (2014) Michael Weller et al. LANCET ONCOLOGY
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
- (2011) D. Lemke et al. CLINICAL CANCER RESEARCH
- Galectin-1 is expressed in early-type neural progenitor cells and down-regulates neurogenesis in the adult hippocampus
- (2011) Yoichi Imaizumi et al. Molecular Brain
- Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response
- (2010) Anna I. Markowska et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More